Showing results (31-40 of 136) with videos related to
Sort By:
Pageof 14
British Journal of Clinical Pharmacology|August 26, 2004
Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitroBryan A Ward, Alan Morocho, Abdullah Kandil, et al.Frontiers in Genetics|November 28, 2012
Impact of the Interaction between 3'-UTR SNPs and microRNA on the Expression of Human Xenobiotic Metabolism Enzyme and Transporter GenesRongrong Wei, Fan Yang, Thomas J Urban, et al.Experimental Neurology|April 14, 2016
Aromatase inhibitors augment nociceptive behaviors in rats and enhance the excitability of sensory neuronsJason D Robarge, Djane B Duarte, Behzad Shariati, et al.Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|June 11, 2011
Morbid obesity and metabolic syndrome in Ossabaw miniature swine are associated with increased platelet reactivityRolf P Kreutz, Mouhamad Alloosh, Khaled Mansour, et al.Bioinformatics (Oxford, England)|June 15, 2015
Cypiripi: exact genotyping of CYP2D6 using high-throughput sequencing dataIbrahim Numanagić, Salem Malikić, Victoria M Pratt, et al.Genetics in Medicine : Official Journal of the American College of Medical Genetics|February 19, 2008
Pharmacogenetic testing of CYP2C9 and VKORC1 alleles for warfarinDavid A Flockhart, Dennis O'Kane, Marc S Williams, et al.Breast Cancer Research and Treatment|March 1, 2006
Analysis of angiogenesis genes from paraffin-embedded breast tumor and lymph nodesBryan P Schneider, Todd C Skaar, George W Sledge, et al.Journal of Medicinal Chemistry|December 26, 2015
Synthesis of Triphenylethylene Bisphenols as Aromatase Inhibitors That Also Modulate Estrogen ReceptorsWei Lv, Jinzhong Liu, Todd C Skaar, et al.The Journal of Pharmacology and Experimental Therapeutics|January 13, 2009
Rapid identification of the hepatic cytochrome P450 2C19 activity using a novel and noninvasive [13C]pantoprazole breath testZeruesenay Desta, Anil Modak, Phuong D Nguyen, et al.The Journal of Pharmacology and Experimental Therapeutics|April 5, 2003
The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activityBryan A Ward, J Christopher Gorski, David R Jones, et al.Pageof 14